---
title: "Why One Drug Company Held Back a Better Drug"
date: 2023-09-07
permalink: /resources/micro/patents-and-drugs
tags:
  - imperfect competition
  - monopoly
  - antitrust
  - patents
category: "monopoly"
type: "podcast"
publisher: "The Daily"
paperurl: 'https://www.nytimes.com/2023/09/07/podcasts/the-daily/gilead-hiv-drug.html'
duration: "38:49"
---

<!-- Google tag (gtag.js) -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-Q95WSVMDNZ"></script>
<script>
  window.dataLayer = window.dataLayer || [];
  function gtag(){dataLayer.push(arguments);}
  gtag('js', new Date());

  gtag('config', 'G-Q95WSVMDNZ');
</script>


**<span class="bold-podcast">Publisher: </span>&nbsp;<span class="text-podcast"> {{ page.publisher }}</span>**

**<span class="bold-podcast">Duration: </span>&nbsp;<span class="text-podcast"> {{ page.duration }}</span>**

**<span class="bold-podcast">Summary from website:</span>**
For decades, drugmakers have argued that patents are critical to bringing new drugs to the market. But in 2004, when a promising H.I.V. treatment emerged, Gilead Sciences decided to slow-walk its release to maximize profit on the company’s existing patents.

Rebecca Robbins, who covers the pharmaceutical industry for The Times, discusses one man’s case and how patents can create perverse incentives to delay new and better drugs.


<p>
  Listen to the podcast here: 
  <a href="https://www.nytimes.com/2023/09/07/podcasts/the-daily/gilead-hiv-drug.html" target="_blank" rel="noopener">
    The Daily – Why One Drug Company Held Back a Better Drug. Drug companies say patents spur innovation. Can they also do the opposite?
  </a>
</p>



**<span class="small-podcast">Link:</span>&nbsp;<span class="links-podcast">[{{ page.paperurl }}]({{ page.paperurl }})</span>**